The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Therapeutic advances in targeting HER2 alterations in NSCLC & remaining challenges
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the development of new agents for managing HER2-positive non-small cell lung cancer (NSCLC). Traditionally treated with chemotherapy and immune checkpoint inhibitors, these patients have limited targeted options. Promising new agents include trastuzumab deruxtecan (T-DXd), an ADC targeting HER2, and HER2-directed TKIs like tucatinib. The Phase II DESTINY-Lung02 trial (NCT04644237) showed a higher response rate in TKIs like tucatinib than in T-DXd. Key questions remain about sequencing these treatments and whether to combine them with chemotherapy. Personalized treatment strategies are crucial for these typically young, non-smoking patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employment – AstraZeneca (I)
Consulting or Advisory Role – Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding – AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses – Janssen Oncology; Janssen Oncology; Roche
